diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Grade I/II Ankle Sprain
Conditions
Grade I/II Ankle Sprain
Trial Timeline
Jul 1, 2009 → Dec 1, 2009
NCT ID
NCT00955513About diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + Placebo
diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + Placebo is a phase 3 stage product being developed by Novartis for Grade I/II Ankle Sprain. The current trial status is completed. This product is registered under clinical trial identifier NCT00955513. Target conditions include Grade I/II Ankle Sprain.
What happened to similar drugs?
0 of 6 similar drugs in Grade I/II Ankle Sprain were approved
Approved (0) Terminated (1) Active (5)
🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00955513 | Phase 3 | Completed |
Competing Products
20 competing products in Grade I/II Ankle Sprain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 27 |
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 32 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 29 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 39 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 26 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 42 |
| Abemaciclib + Letrozole | Eli Lilly | Phase 2 | 42 |
| Pirtobrutinib + Mosunetuzumab | Eli Lilly | Phase 2 | 42 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 21 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Mirvetuximab soravtansine + Carboplatin | AbbVie | Phase 2 | 39 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 42 |
| Acalabrutinib + Obinutuzumab | AstraZeneca | Phase 2 | 42 |
| Olaparib Pill + AZD6738 | AstraZeneca | Phase 2 | 35 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Efineptakin alfa + Pembrolizumab | Merck | Phase 2 | 42 |
| Pembrolizumab | Merck | Phase 2 | 39 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 35 |
| Cilengitide | Merck | Phase 2 | 31 |
| Avelumab | Merck | Phase 2 | 35 |